Parkinson’s Disease (PD) is a progressive disorder that is caused by the degeneration of nerve cells in the part of the brain called the substantia nigra, which controls movement. The cause of PD remains unknown but it has long been hypothesized that exposure to environmental risk factors may be one cause, along with an inherited susceptibility.
The majority of cases are thought to arise sporadically, although up to 20% of people with Parkinson’s Disease also have a first-degree relative with PD.
Parkinson's Disease Epidemiology Segmentation in 7MM from 2018 to 2030
- Total Prevalent Cases of Parkinson’s Disease
- Gender-specific Cases of Parkinson’s Disease
- Severity-specific Prevalence of Parkinson’s Disease
- Age-specific Cases of Parkinson’s Disease
- Prevalent Cases of Parkinson’s Disease based on the onset
Parkinson's Disease Epidemiology Insights Observed in 2020
- The total prevalent population of Parkinson’s Disease in the United States was observed to be 1,073,894 in the year 2020.
Parkinson's Disease Market Insights
As per DelveInsight analysis, the Parkinson's Disease market size was found to be USD 1390.1 million in the US in the year 2020.
Parkinson's Disease Market Drivers
- Development of Adherence-Friendly Drug Formulations
- Development of Drug for Better Treatment of Motor Symptoms
- Gene Therapy and Stem Cell Therapy
Parkinson's Disease Market Barriers
- Inadequate Knowledge of Pathophysiology
- Lack of Diagnostic Measures and Methods
- Lack of Efficacy of Existing Therapies
Parkinson's Disease Emerging Therapies
The emerging drugs in the Parkinson's Disease market are
- Atuzaginstat
- Tavapadon
- IPX203
- P2B001
- CVN424, and several others
Parkinson's Disease Key Players
The key companies in the Parkinson's Disease market are
- Cortexyme
- Cerevel Therapeutics
- Amneal Pharmaceuticals
- Pharma Two B
- Cerevance Beta, and several others